机构投资者增加了AbbVie的股份,尽管其收入低于预期,而且公司股票销售量低于预期。 Institutional investors boosted AbbVie shares despite below-expected earnings and executive stock sales.

第二季度,几个机构投资者,包括Peterson财富服务公司和PKO投资管理公司,大大增加了对AbbVie公司的股权,AbbVie公司报告说,每股2.97美元的Q2收入低于预期,而年收入则增长了6.6%,达到154.2亿美元。 In the second quarter, several institutional investors, including Peterson Wealth Services and PKO Investment Management, significantly increased their stakes in AbbVie, which reported Q2 earnings of $2.97 per share—below expectations—while revenue rose 6.6% year-over-year to $15.42 billion. 股价为228.06美元,市场上限为4 028.7亿美元,具有协商一致的“货币购买”评级,价格目标是234.80美元。 The stock, trading at $228.06 with a $402.87 billion market cap, has a consensus "Moderate Buy" rating and a price target of $234.80. 8月,行政主管Azita Saleki-Gerhardt和Nicholas Donoghoe共出售55 665股股票,净额约为1 100万美元。 Executives Azita Saleki-Gerhardt and Nicholas Donoghoe sold a combined 55,665 shares in August, netting about $11 million. AbbVie的股息收益为2.9%,年支付额为6.56美元,尽管支付比率为312.38%。 AbbVie’s dividend yield is 2.9% with an annual payout of $6.56, though the payout ratio is 312.38%. 关键产品包括Humira、Skyrizi、Rinvoq、Imbruvica和Venclexta。 Key products include Humira, Skyrizi, Rinvoq, Imbruvica, and Venclexta.